SYDNEY, Australia – (BUSINESS WIRE) – SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has added saliva to the list of validated samples for their PlexPCR® SARS-CoV-2 qPCR diagnostics for COVID-19 sales throughout Europe#. A preferred sample type for self-collection and compliance testing programs, the saliva claim will expand the applicability of the SpeeDx COVID-19 workflow, and in partnership with the Molgen series of automation, it will further support ultra-high throughput testing markets.
“Our automation-compatible workflow is very popular in large-scale laboratories along with the flexibility to pair with a range of existing laboratory equipment to maximize instrument capacity,” said Cassandra Ingles, Director of Clinical Operations. “As COVID-19 test patterns evolve, we will continue to respond to the changing needs of the laboratories we support and expand requirements for key sample types, in addition to making it easier to integrate into laboratory data information systems without the need for third-party software. . ”
SpeeDx’s new head office facilities in Sydney have expanded the company’s production capacity to support the growth in export sales, and as international travel increases, demand for both COVID-19 and other respiratory tests is underway. PlexPCR® RespiVirus, a highly multiplexed 11-target respiratory viral panel that includes influenza A, influenza B, and respiratory syncytial virus, can be run in parallel with PlexPCR® SARS-CoV-2 for a more comprehensive test solution, and both are compatible with SpeeDx PlexPrep ™ robotic fluid handling, which has recently been shown to increase throughput by 155% and reduce hands-on time by 19% compared to a sample-to-answer test solution.1 Additional respiratory tests are about to be released this year, including PlexPCR® RespiBacteria with targeted detection and differentiation of Bordatella pertussis, B. parapertussis, B. holmesii, and Mycoplasma pneumoniae.
SpeeDx also has a comprehensive range of reagents to support the study of COVID-19 variants of concern, including PlexPrime® SARS-CoV-2 Alpha / Beta / Gamma + * which contains mutations that can distinguish circulating Omicron strains including both BA1 and BA2 variants. Compatible with standard qPCR and fluid handling instrumentation, the PlexPrime® The SARS-CoV-2 Genotyping * series is designed to help laboratories with variant monitoring practices integrate with their existing SARS-Cov-2 test workflow, increasing the number of samples screened for variants, improving the ability to observe population anomalies and reduces labor and costs associated with parallel sequence analysis of a subset of positive samples.
SpeeDx was founded in 2009 and is an Australian-based private company with subsidiaries in Austin and London and distributors throughout Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to provide comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. For more information about SpeeDx please see: https://plexpcr.com
#not commercially available for use in the UK, saliva extension during review of TGA for use in Australia
PryceTM one eel. Evaluation of a PlexZyme-Based PCR assay and assessment of COVID-19 Surge Testing throughput compared to Coba’s SARS-CoV-2. Bacteria. 2021 Sep; 10 (9): 1088.